10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
AMGEN INC | |||
Ticker: AMGN Fiscal Year: 2022 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 9, 2023) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 26,323 | 25,979 | 25,424 |
| Operating expenses: | |||
| Cost of sales | 6,406 | 6,454 | 6,159 |
| Research and development | 4,434 | 4,819 | 4,207 |
| Acquired in-process research and development | 0 | 1,505 | 0 |
| Selling, general and administrative | 5,414 | 5,368 | 5,730 |
| Other | 503 | 194 | 189 |
| Total operating expenses | 16,757 | 18,340 | 16,285 |
| Operating income | 9,566 | 7,639 | 9,139 |
| Interest expense, net | (1,406) | (1,197) | (1,262) |
| Other (expense) income, net | (814) | 259 | 256 |
| Income before income taxes | 7,346 | 6,701 | 8,133 |
| Provision for income taxes | 794 | 808 | 869 |
| Net income | 6,552 | 5,893 | 7,264 |
| Earnings per share: | |||
| Basic (in usd per share) | 12.18 | 10.34 | 12.40 |
| Diluted (in usd per share) | 12.11 | 10.28 | 12.31 |
| Shares used in the calculation of earnings per share: | |||
| Basic (in shares) | 538 | 570 | 586 |
| Diluted (in shares) | 541 | 573 | 590 |
| Product and Service | |||
| Product sales | |||
| Total revenues | 24,801 | 24,297 | 24,240 |
| Other revenues | |||
| Total revenues | 1,522 | 1,682 | 1,184 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
AMGEN INC | |||
Ticker: AMGN Fiscal Year: 2022 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 9, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net income | $ 6,552 | 5,893 | 7,264 |
| Other comprehensive income (loss), net of reclassification adjustments and taxes: | |||
| Gains (losses) on foreign currency translation | 496 | (135) | 9 |
| Gains (losses) on cash flow hedges | 67 | 324 | (438) |
| Losses on available-for-sale securities | 0 | (1) | (21) |
| Other | 2 | 1 | (7) |
| Other comprehensive income (loss), net of taxes | 565 | 189 | (457) |
| Comprehensive income | 7,117 | 6,082 | 6,807 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
AMGEN INC | |||
Ticker: AMGN Fiscal Year: 2022 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 9, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash flows from operating activities: | |||
| Net income | $ 6,552 | 5,893 | 7,264 |
| Depreciation, amortization and other | 3,417 | 3,398 | 3,601 |
| Stock-based compensation expense | 401 | 341 | 330 |
| Deferred income taxes | (1,198) | (453) | (287) |
| Acquired in-process research and development | 0 | 1,505 | 0 |
| Adjustments for equity method investments | 891 | 33 | 65 |
| Loss on divestiture | 567 | 0 | 0 |
| Other items, net | (176) | (262) | (260) |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Trade receivables, net | (746) | (429) | (427) |
| Inventories | (742) | (165) | (215) |
| Other assets | 258 | (237) | 129 |
| Accounts payable | 154 | (69) | 45 |
| Accrued income taxes, net | (647) | (854) | (249) |
| Long-term tax liabilities | 229 | 204 | (482) |
| Other liabilities | 761 | 356 | 983 |
| Net cash provided by operating activities | 9,721 | 9,261 | 10,497 |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (2,587) | (8,900) | (8,477) |
| Proceeds from sales of marketable securities | 98 | 4,403 | 2,597 |
| Proceeds from maturities of marketable securities | 1,120 | 8,831 | 4,381 |
| Purchases of property, plant and equipment | (936) | (880) | (608) |
| Cash paid for acquisitions, net of cash acquired | (3,839) | (2,529) | 0 |
| Purchases of equity method investments | (18) | (157) | (3,219) |
| Proceeds from Divestiture of Businesses, Net of Cash Divested | 130 | 0 | 0 |
| Other | (12) | (35) | (75) |
| Net cash (used in) provided by investing activities | (6,044) | 733 | (5,401) |
| Cash flows from financing activities: | |||
| Net proceeds from issuance of debt | 6,919 | 4,945 | 8,914 |
| Extinguishment of debt | (297) | 0 | 0 |
| Repayment of debt | 0 | (4,150) | (6,450) |
| Repurchases of common stock | (6,360) | (4,975) | (3,486) |
| Dividends paid | (4,196) | (4,013) | (3,755) |
| Other | (103) | (78) | (90) |
| Net cash used in financing activities | (4,037) | (8,271) | (4,867) |
| (Decrease) increase in cash and cash equivalents | (360) | 1,723 | 229 |
| Cash and cash equivalents at beginning of year | 7,989 | 6,266 | |
| Cash and cash equivalents at end of year | 7,629 | 7,989 | 6,266 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
AMGEN INC | ||
Ticker: AMGN Fiscal Year: 2022 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2022 10-K (Filed: Feb 9, 2023) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2022 | Dec 31, 2021 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 7,629 | 7,989 |
| Marketable securities | 1,676 | 48 |
| Trade receivables, net | 5,563 | 4,895 |
| Inventories | 4,930 | 4,086 |
| Other current assets | 2,388 | 2,367 |
| Total current assets | 22,186 | 19,385 |
| Property, plant and equipment, net | 5,427 | 5,184 |
| Intangible assets, net | 16,080 | 15,182 |
| Goodwill | 15,529 | 14,890 |
| Other noncurrent assets | 5,899 | 6,524 |
| Total assets | 65,121 | 61,165 |
| LIABILITIES AND STOCKHOLDERS EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 1,572 | 1,366 |
| Accrued liabilities | 12,524 | 10,731 |
| Current portion of long-term debt | 1,591 | 87 |
| Total current liabilities | 15,687 | 12,184 |
| Long-term debt | 37,354 | 33,222 |
| Long-term tax liabilities | 5,757 | 6,594 |
| Other noncurrent liabilities | 2,662 | 2,465 |
| Contingencies and commitments | ||
| Stockholders equity: | ||
| Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding534.0 shares in 2022 and 558.3 shares in 2021 | 32,514 | 32,096 |
| Accumulated deficit | (28,622) | (24,600) |
| Accumulated other comprehensive loss | (231) | (796) |
| Total stockholders equity | 3,661 | 6,700 |
| Total liabilities and stockholders equity | 65,121 | 61,165 |
| External Links | |
| AMGEN INC (AMGN) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |